Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

NYU Langone Heart

PharmaDeviceNews NYU Langone Heart

$A representative image illustrating TNX-103 heart failure clinical research after Tenax Therapeutics’ Phase 3 LEVEL trial missed its primary exercise-capacity endpoint in pulmonary hypertension associated with heart failure with preserved ejection fraction.$

Medical Devices & Diagnostics

Stents, kidney disease and heart failure AI: What could NYU Langone’s AHA 2026 data reveal?

by Pallavi Madhiraju
November 6, 2026
0 Comments

NYU Langone previews AHA 2026 studies on coronary survival, heart failure alerts and air pollution. See which findings could influence care.

Read More

Latest news and features

CareValidate promises same-day GLP-1 delivery, but can it solve telehealth’s last-mile problem?
Lynk Pharmaceuticals advances zemprocitinib towards China approval after positive Phase 3 rheumatoid arthritis results
Kos Biotechnology Partners backs Fathom Therapeutics’ US$55m AI drug discovery financing
Bausch Health presents 1,630-patient liver disease study at AASLD 2026
Tandem Diabetes Care’s new CEO inherits a growing $1bn business. Can she deliver profitability?
UL Solutions studied 470 million training activities. Are pharma workers really learning their SOPs?
Thermo Fisher Scientific’s new $5bn buyback: A confidence signal or capital allocation test?
Bio-Thera’s BAT2506 wins a China first, but can it challenge Johnson & Johnson’s Simponi?
Stents, kidney disease and heart failure AI: What could NYU Langone’s AHA 2026 data reveal?
BRC Therapeutics hires Jazz Pharmaceuticals veteran, but can its cannabinoid pipeline deliver?
Eli Lilly brings Zepbound and Foundayo to Hims & Hers, but who gains most from the deal?
Revelation Biosciences sees a $94bn Gemini market, but can it fund the clinical test?

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

TC Energy approves C$3bn pipeline projects as AI power demand drives gas expansion
Cloudflare revenue jumps 39% to $782.5m, but GAAP losses raise a bigger question
US expands Cuba sanctions to technology, shipping and manufacturing sectors
Freeport-McMoRan (FCX) approves $4.5bn copper expansion as shares fall 7.5%
Adani Ports (ADANIPORTS) targets Evos in €2.56bn deal, but can debt-funded expansion deliver returns?

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.